MYGN - Myriad Genetics Names George Daneker Jr. MD as President and Chief Clinical Officer of Oncology | Benzinga
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.
Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad's oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombination deficiency (HRD) testing.
"We are pleased to welcome George to Myriad. He is an accomplished healthcare leader with a proven ability to spearhead and manage the development of precision medicine and clinical research programs in the oncology space," said Paul J. Diaz, president and CEO, Myriad Genetics. "His strategic vision and combined clinical, research and academic experience will be instrumental in leading the continued innovation, growth and development of our oncology portfolio, including our planned product expansions into liquid biopsy and minimal residual disease (MRD) ...